Why am I passionate about this?
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
John's book list on the challenges of discovering breakthrough medicines
Why did John love this book?
Legislators and healthcare insurers are seeking ways to slash healthcare costs, often focusing on cutting the costs of medicines through schemes like price controls. Yet, drugs make up only about 13 percent of the money paid on healthcare. This book does a great job of explaining what is behind the pricing of new drugs but, more importantly, shows that all life-saving drugs eventually become low-cost generics – truly a Great American Drug Deal.
This book scrutinizes all players in the healthcare industry and offers new ideas for cost-saving measures, such as closing loopholes, dealing with bad actors, and educating consumers. If you want to understand how best to balance innovation and affordability, this book is a must-read.
2 authors picked The Great American Drug Deal as one of their favorite books, and they share why you should read it.
Developing life-changing drugs is risky and expensive—but that’s not what makes them unaffordable.Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need.Do we really have to choose between affordability and innovation?In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive No. The pharmaceutical industry’s commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced…